Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 8,827 shares, a growth of 68.7% from the July 15th total of 5,232 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,750 shares, the short-interest ratio is presently 1.9 days.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in Invesco Biotechnology & Genome ETF by 22.3% during the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 5.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock valued at $2,389,000 after purchasing an additional 2,103 shares in the last quarter. Osaic Holdings Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 9.9% during the 2nd quarter. Osaic Holdings Inc. now owns 9,441 shares of the company’s stock valued at $605,000 after purchasing an additional 852 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Invesco Biotechnology & Genome ETF by 74.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after purchasing an additional 245 shares during the period. Finally, Blair William & Co. IL increased its position in shares of Invesco Biotechnology & Genome ETF by 150.0% during the 3rd quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock valued at $70,000 after purchasing an additional 600 shares during the period.
Invesco Biotechnology & Genome ETF Stock Up 0.6%
Invesco Biotechnology & Genome ETF stock traded up $0.58 during trading hours on Tuesday, hitting $95.30. 38,457 shares of the company traded hands, compared to its average volume of 13,046. Invesco Biotechnology & Genome ETF has a 1-year low of $67.41 and a 1-year high of $95.42. The firm has a market cap of $300.19 million, a P/E ratio of 20.44 and a beta of 0.70. The firm’s 50-day simple moving average is $89.71 and its two-hundred day simple moving average is $83.84.
Invesco Biotechnology & Genome ETF Company Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
Featured Stories
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
